Drugs / Ciplukan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06887322 | Feb → Apr 2025 overdue | psoriasis | Padjadjaran University | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ciplukan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06887322 ↗ |
| Known as | Physalis angulata Linn. | “Ciplukan (Physalis angulata Linn.) contains seco-steroids and flavonoids, which exhibit anti-inflammatory, antiproliferative, and immunosuppressive effects.” NCT06887322 ↗ |
| Route | Topical | “topical formulation containing 20% ciplukan (Physalis angulata Linn.) extract” NCT06887322 ↗ |